Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
2009 ◽
Vol 9
(1)
◽
pp. 67-72
◽
Keyword(s):
2004 ◽
Vol 53
(10)
◽
pp. 528-533
◽
Keyword(s):
2007 ◽
Vol 7
(11)
◽
pp. 1763-1777
◽
Keyword(s):
Keyword(s):
2004 ◽
Vol 32
(11)
◽
pp. 2199-2206
◽
Keyword(s):